Tisagenlecleucel and Lisocabtagene Maraleucel: Comparative Efficacy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Schuster, Stephen J. [1 ]
Zhang, Jie [2 ]
Yang, Hongbo [3 ]
Agarwal, Abhijit [2 ]
Tang, Wenxi [3 ]
Prieto, Marcela Martinez [2 ]
Bollu, Vamsi [2 ]
Kuzan, David [2 ]
Maziarz, Richard [4 ]
Kersten, Marie Jose [5 ]
机构：
[1] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Boston, MA USA
[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
ABCL; diffuse large B-cell lymphoma; CAR-T cell therapy; MAIC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-166
引用
收藏
页码：S380 / S381
页数：2
相关论文
共 50 条
  • [31] Lisocabtagene maraleucel, a therapeutic alternative to autograft for primary refractory large B-cell lymphoma or in early relapse?
    Marieton, Elena Robin
    HEMATOLOGIE, 2023, 29 (03): : 150 - 152
  • [32] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [33] Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew
    Wang, Michael
    Arnason, Jon
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott R.
    Ghosh, Nilanjan
    Dehner, Christine
    Kim, Yeonhee
    Ogasawara, Ken
    Kostic, Ana
    Siddiqi, Tanya
    BLOOD, 2024, 143 (05) : 404 - 416
  • [34] Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
    Chanut, Mathilde
    Herbaux, Charles
    BULLETIN DU CANCER, 2023, 110 (10) : 986 - 988
  • [35] Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
    Parker, Christopher
    Liu, Fei Fei
    Deger, Kristen A. A.
    Franco-Villalobos, Conrado
    Proskorovsky, Irina
    Keating, Scott J. J.
    Sorensen, Sonja
    ADVANCES IN THERAPY, 2023, 40 (05) : 2355 - 2374
  • [36] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [37] EFFICACY OF AXICABTAGEN CILOLEUCEL VERSUS TISAGENLECLEUCEL IN THE TREATMENT OF RELAPSED OR REFRACTORY DIFFUSE LARGE CELL LYMPHOMA B IN SPAIN
    Mariana, Bastos-Oreiro
    Ana, De las Heras
    Maria, Presa
    Miguel Angel, Casado
    Carlos, Pardo
    Victoria, Martin-Escudero
    Anna, Sureda
    HAEMATOLOGICA, 2021, 106 (10) : 292 - 293
  • [38] Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
    Christopher Parker
    Fei Fei Liu
    Kristen A. Deger
    Conrado Franco-Villalobos
    Irina Proskorovsky
    Scott J. Keating
    Sonja Sorensen
    Advances in Therapy, 2023, 40 : 2355 - 2374
  • [39] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
    Qi, Cynthia Z.
    Bollu, Vamsi
    Yang, Hongbo
    Dalal, Anand
    Zhang, Su
    Zhang, Jie
    CLINICAL THERAPEUTICS, 2021, 43 (08) : 1300 - +
  • [40] Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
    Andreadis, Charalambos
    Tam, Constantine S.
    Borchmann, Peter
    Jaeger, Ulrich
    McGuirk, Joseph P.
    Holte, Harald
    Waller, Edmund K.
    Jaglowski, Samantha
    Bishop, Michael R.
    Foley, Stephen Ronan
    Westin, Jason R.
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Salles, Gilles A.
    Schuster, Stephen J.
    Bachanova, Veronika
    Maziarz, Richard T.
    Van Besien, Koen
    Izutsu, Koji
    Magenau, John M.
    Wagner-Johnston, Nina D.
    Kato, Koji
    Corradini, Paolo
    Tiwari, Ranjan
    Awasthi, Rakesh
    Lawniczek, Tomasz
    Eldjerou, Lamis K.
    Kersten, Marie Jose
    BLOOD, 2019, 134
12345